Zevra Therapeutics (ZVRA) Beginning Cash Balance (2016)

Zevra Therapeutics (ZVRA) reported Beginning Cash Balance of $18.6 million for Q1 2016.

Zevra Therapeutics (ZVRA) Beginning Cash Balance (2016) Analysis & Trends

Zevra Therapeutics has reported Beginning Cash Balance for 1 years, with the latest figure at $18.6 million in Q1 2016.

For the quarter ending Q1 2016, Beginning Cash Balance changed N/A year-over-year to $18.6 million; the trailing twelve-month figure through Dec 2016 stood at $18.6 million (changed N/A YoY), and the FY2016 full-year result was $18.6 million, changed N/A from the prior year.
Beginning Cash Balance for Q1 2016 stood at $18.6 million.
The five-year high for Beginning Cash Balance was $18.6 million in Q1 2016, with the low at $18.6 million in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Zevra Therapeutics	796.95 Mn	596.33 Mn	34.30 Mn

Download Data

Date	Value
Mar 31, 2016	18.62 Mn
Mar 31, 2016	18.62 Mn